Biblio

2024
Mediratta K, El-Sahli S, Marotel M, Awan MZ, Kirkby M, Salkini A, Kurdieh R, Abdisalam S, Shrestha A, Di Censo C, et al. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model. Front Immunol. 2024;15:1366197.
Tripathi T, Yadav J, Janjua D, Chaudhary A, Joshi U, Senrung A, Chhokar A, Aggarwal N, Bharti AChandra. Targeting Cervical Cancer Stem Cells by Phytochemicals. Curr Med Chem. 2024.
Cancilla D, Rettig MP, Karpova D, Thakellapalli H, Singh M, Meyers MJ, Ruminski PG, Christ S, Chendamarai E, Gao F, et al. Targeting CXCR4, VLA-4 and CXCR2 for Hematopoietic Stem Cell Mobilization. Blood Adv. 2024.
Zhu C, Ke S, Li Y, Zhang W, Che Y, Zhang R, Huang P, Xu T. Targeting DEP domain containing 1 in anaplastic thyroid carcinoma: Implications for stemness regulation and malignant phenotype suppression. Heliyon. 2024;10(5):e27150.
Liu C-C, Chen L, Cai Y-W, Chen Y-F, Liu Y-M, Zhou Y-J, Shao Z-M, Da Yu K-. Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer. Cell Rep Med. 2024:101396.
Ashoub MHossein, Razavi R, Heydaryan K, Salavati-Niasari M, Amiri M. Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology. Eur J Med Res. 2024;29(1):224.
Leung WK, Chavez AGTorres, French-Kim M, Shafer P, Mamonkin M, Hill LQC, Kuvalekar M, Velazquez Y, Watanabe A, Watanabe N, et al. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024.
Kakafika MG, Lyta AA, Gavriilidis GI, Tsiftsoglou SA, Miliotou AN, Pappas IS, Vizirianakis IS, Papadopoulou LC, Tsiftsoglou AS. Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K‑562 and colorectal HCT‑116 cancer cells. Int J Oncol. 2024;64(4).
Venkatraman S, Balasubramanian B, Thuwajit C, Meller J, Tohtong R, Chutipongtanate S. Targeting MYC at the intersection between cancer metabolism and oncoimmunology. Front Immunol. 2024;15:1324045.
Ahmad SSayeed, Lim JHo, Ahmad K, Chun HJin, Hur SJin, Lee EJu, Choi I. Targeting myostatin using quercetin as a media supplement to improve myogenesis for cultured meat production: An and study. Curr Res Food Sci. 2024;8:100678.
Hong S-H, Castro G, Wang D, Nofsinger R, Kane M, Folias A, Atkins AR, Yu RT, Napoli JL, Sassone-Corsi P, et al. Targeting nuclear receptor corepressors for reversible male contraception. Proc Natl Acad Sci U S A. 2024;121(9):e2320129121.
Dong H, He X, Zhang L, Chen W, Lin Y-C, Liu S-B, Wang H, Nguyen LXuan Truon, Li M, Zhu Y, et al. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat Cancer. 2024.
Long Y, Yang B, Lei Q, Gao F, Chen L, Chen W, Chen S, Ren W, Cao Y, Xu L, et al. Targeting Senescent Alveolar Epithelial Cells Using Engineered Mesenchymal Stem Cell-Derived Extracellular Vesicles To Treat Pulmonary Fibrosis. ACS Nano. 2024.
Rossdam C, Brand S, Beimdiek J, Oberbeck A, Albers MDarius, Naujok O, Buettner FFR. Targeting the glycan epitope type I N-acetyllactosamine enables immunodepletion of human pluripotent stem cells from early differentiated cells. Glycobiology. 2024.
Singh D, Sahoo A. Targeting the Key Signaling Pathways in Breast Cancer: From Molecular Mechanism to Therapeutic Interventions. Recent Pat Anticancer Drug Discov. 2024.
Zhang Y, Zhang Y, Song J, Cheng X, Zhou C, Huang S, Zhao W, Zong Z, Yang L. Targeting the "tumor microenvironment": RNA-binding proteins in the spotlight in colorectal cancer therapy. Int Immunopharmacol. 2024;131:111876.
Luo H, Li Q, Hong J, Huang Z, Deng W, Wei K, Lu S, Wang H, Zhang W, Liu W. Targeting TNF/IL-17/MAPK pathway in h leukemia: effects of OUL35, KJ-Pyr-9, and CID44216842. Haematologica. 2024.
Zhou J, Xu H, Li X, Liu H, Sun Z, Li J, Tang Y, Gao H, Zhao K, Ding C, et al. Targeting tumorous Circ-E-Cadherinencoded C-E-Cad inhibits the recruitment and function of breast cancer-associated myeloid-derived suppressor cells. Pharmacol Res. 2024:107204.
Gutova M, Hibbard JC, Ma E, Natri HM, Adhikarla V, Chimge N-O, Qiu R, Nguyen C, Melendez E, Aguilar B, et al. Targeting Wnt signaling for improved glioma immunotherapy. Front Immunol. 2024;15:1342625.
Calabrese EJ, Pressman P, A Hayes W, Kapoor R, Dhawan G, Agathokleous E, Calabrese V. Taurine induces hormesis in multiple biological models: May have transformative implications for overall societal health. Chem Biol Interact. 2024:110930.
Badry MO, Osman AK, Aboulela M, Gafar S, Nour IH. Taxonomic implications of normal and abnormal stomatal complexes in Indigofera L. (Indigofereae, Faboideae, Fabaceae). Protoplasma. 2024.
Ueki H, Ogawa C, Goto H, Nishi M, Yamanaka J, Mochizuki S, Nishikawa T, Kumamoto T, Nishiuchi R, Kikuta A, et al. TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia. Int J Hematol. 2024.
Yu Y, Liu L, Cao J, Huang R, Duan Q, Ye S-D. Tbl1 promotes Wnt/β-catenin signaling-induced degradation of the Tcf7l1 protein in mouse ESCs. J Cell Sci. 2024.
Yi C, Song H, Liang H, Ran Y, Tang J, Chen E, Li F, Fu L, Wang Y, Chen F, et al. TBX3 reciprocally controls key trophoblast lineage decisions in villi during human placenta development in the first trimester. Int J Biol Macromol. 2024:130220.
Bulger EA, Muncie-Vasic I, Libby ARG, McDevitt TC, Bruneau BG. TBXT dose sensitivity and the decoupling of nascent mesoderm specification from EMT progression in 2D human gastruloids. Development. 2024.

Pages